New NASDAQ Alert [Inside]

AwesomeStocks Don’t want emails from us anymore? Click [here]( to unsubscribe. Hello! New Alert: Bionomics Limited (NASDAQ: BNOX) BNOX is a recent high volatility opportunity that rallied +35% intraday following our last alert. Now, BNOX could present another opportunity for increased gains. In addition, BNOX announced breaking news this morning. As a reminder, BNOX is a “clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (“CNS”) disorders with high unmet medical need”. BNOX is “advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute treatment of Social Anxiety Disorder (SAD) and chronic treatment of Post-Traumatic Stress Disorder (PTSD)”. According to the National Alliance on Mental Illness, “Anxiety disorders are the most common mental health concern in the United States. Over 40 million adults in the U.S. (19.1%) have an anxiety disorder.” Social Anxiety Disorder, sometimes called social phobia, is an “anxiety disorder characterized by extreme fear or anxiety in one or more social settings”. According to the NIH, an “estimated 7.1% of U.S. adults had social anxiety disorder in the past year”. As the company further explains: “Formulated as a solid oral tablet, BNC210 is a negative allosteric modulator of the α7 nicotinic acetylcholine receptor under development for the acute treatment of SAD and chronic treatment of Post-Traumatic Stress Disorder (PTSD).” Importantly: “BNC210 has been given FDA Fast Track designation for acute treatment of SAD and other anxiety-related disorders, and for treatment of PTSD and other trauma and stressor-related disorders.” In addition, BNOX has a “strategic partnership with Merck & Co., Inc. (known as MSD outside the United States and Canada) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer’s disease and other central nervous system conditions”. Furthermore: “Bionomics’ pipeline also includes preclinical assets that target Kv3.1/3.2 and Nav1.7/1.8 ion channels being developed for CNS conditions of high unmet need”. BNOX has announced multiple accomplishments recently. In July, the company announced: “Bionomics Announces Key Leadership Updates to Drive U.S.-Focused Transformation and Next Stage of Strategic Growth” Here are the company’s comments from this press release: “With the addition of multiple U.S.-based and highly accomplished industry executives, we believe we have positioned Bionomics for sustainable growth as we continue to advance our corporate evolution,” said Spyros Papapetropoulos, M.D., Ph.D., President and CEO of Bionomics. “Collectively, Tim, Julie, and Atul bring over 50+ years of experience in the biopharma sector, and diverse expertise in developing and commercializing drug products. I am confident that their complementary skill sets will be instrumental in leading the Company into a new era focused on the fiscally efficient advancement of our late-stage programs. I would like to thank Connor for his contributions to the Company and wish him well for the future, as well as Adrian Hinton, Acting CFO for the last four years who will continue supporting the Company as a Financial Controller. In addition, I look forward to working with Alan in his new role as Chair of the Board and would like to thank Errol for his many contributions to Bionomics.” In addition, in July, the company stated: “Bionomics is approaching several very important value-inflection milestones for our late-stage clinical development program with BNC210, a first and best-in class α7 nicotinic receptor negative allosteric modulator under evaluation in patients with Social Anxiety Disorder (SAD) and Post-Traumatic Stress Syndrome (PTSD), in the coming quarters,” said Spyros Papapetropoulos, M.D. Ph.D., Bionomics’ President and CEO; “As we continue our transformation to a U.S.-focused organization, we would like to deepen our engagement with the broadest range of potential investors and maximize Bionomics’ access to capital and financing opportunities while reducing costs and compliance obligations associated with a dual listing. We believe delisting from the ASX and focusing on a primary listing on the NASDAQ will increase our trading volume and liquidity, and consequently will enable Bionomics to fulfill these objectives and support continued value creation for patients, investors, and our stakeholders.” Most recently, the company announced: “Bionomics Completes Last Patient Last Visit in the Phase 2b ATTUNE Study for Post-Traumatic Stress Disorder (PTSD) and Confirms Expected 2023 Milestones with its Lead Asset BNC210” Here are the highlights from this press release: - “The last patient last visit has been completed in the Phase 2b ATTUNE study of BNC210 for the treatment of PTSD” - “Topline results from Phase 2b ATTUNE study of BNC210 in patients with PTSD are expected by the end of September 2023” - “An end-of-phase 2 (EoPh2) meeting with the U.S. Food and Drug Administration (FDA) has been scheduled for September 2023 to review results from the Phase 2 PREVAIL study in patients with Social Anxiety Disorder (SAD) and to obtain feedback on a proposed Phase 3 registrational program” - “Bionomics is scheduled to delist from the Australian Securities Exchange on 28 August 2023” Here are the company’s comments from this press release: “We continue our strong momentum with our fast track designated BNC210, with a robust clinical and regulatory milestone-rich year in both SAD and PTSD, two highly prevalent neuropsychiatric disorders with significant unmet needs,” said Spyros Papapetropoulos, M.D., Ph.D., President and CEO of Bionomics. “I would like to thank study participants, their families, our clinical site investigators and their staff and our clinical team for their contributions towards achieving completion of the ATTUNE study. We also look forward to our EoPh2 meeting with the FDA next month, where we will discuss our promising results from the PREVAIL study in SAD and the proposed Phase 3 clinical program.” In addition, just this morning, the company announced: “Bionomics Announces Update on the α7 Nicotinic Acetylcholine Receptor (nAChR) Positive Allosteric Modulator (PAM) Collaboration with MSD” Here are the highlights from this press release: - “Bionomics has collaborated with MSD to identify novel α7 nAChR PAMs suitable for the treatment of cognitive disorders like Alzheimer’s Disease” - “Based on the learnings from Bionomics’ candidate BNC375, additional candidates have been developed with improved drug like and pharmacological properties that are currently in Phase 1 safety, tolerability, pharmacokinetics and biomarker studies” BNOX could be in a position to experience increased growth. Make sure to do your own due diligence. Sources: [NAMI]( [ADAA]( [ADAA2]( [NIH]( [MHA]( [PR1]( [PR2]( [PR3]( [PR4]( [PR5]( [PR6]( [PR7]( [PR8]( [Website]( [Chart]( Happy Trading! AwesomeStocks Note: We encourage all traders and investors to develop personal trading rules that you can follow and that work for you. Always protect your downside and note that we alert extremely volatile short-term opportunities. Before investing in securities, you should always consult with your financial, tax and legal advisor and never invest money you cannot afford to lose. DISCLAIMER You should read and understand this disclaimer in its entirety before joining the website or email/blog list of AwesomeStocks.com (the “Publisher”). The information (collectively the “Advertisement”) disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, and/or losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply. To unsubscribe from receiving promotional text messages to your phone sent via an autodialer, using your phone reply to the sender’s phone number with the word STOP or HELP for help. The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at www.sec.gov; the Financial Industry Regulatory Authority (the "FINRA") at www.FINRA.org, and relevant State Securities Administrator website and the OTC Markets website at www.otcmarkets.com. The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at www.sec.gov/consumer/cyberfr.htm, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete. The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial and/or legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete. Owners and operators of the Publisher have been compensated ten thousand dollars by bank wire transfer on 8/28/23 for the distribution of this advertisement about BNOX dated 9/14/23. Previously, owners and operators of the Publisher have been compensated ten thousand dollars by bank wire transfer on 8/28/23 for the distribution of a prior advertisement about BNOX. Previously, owners and operators of the Publisher have been compensated twelve thousand five hundred dollars by bank wire transfer on 3/8/23 for the distribution of a prior advertisement about BNOX. The Publisher and its owners and operators hold no stocks or bonds in companies discussed in the Advertisement. Owners and operators of the Publisher own several newsletters, therefore you may receive multiple publications and emails featuring companies at different or the same time. You are receiving this report/release because you subscribed to receive it at our website or through a third-party site. All our newsletters include an "unsubscribe" link, and you can remove yourself at any time from our newsletters by clicking on that "unsubscribe" link. You can also contact us at info@AwesomeStocks.com to change your information at any time. By your subscription to our profiles, the viewing of this profile and/or use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be viewed at the following link: www.AwesomeStocks.com/Disclaimer and www.AwesomeStocks.com/Privacy-Policy By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of (1) a client company, (2) the party issuing or preparing the information for the company, or (3) other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink. Our records indicate that {EMAIL} requested and confirmed to be added to AwesomeStocks.com on March 5, 2023. [Click Here To Unsubscribe]( 6020 Bent Pine Dr Orlando Florida 32822 USA [Unsubscribe]( | [Change Subscriber Options](